Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: The costs and utilities of MS patients in the Netherlands

Journal of Medical Economics

Volumn 16, Issue 7, 2013, Pages 939-950

  Karampampa, Korinna ^a,b   Gustavsson, Anders ^a,b   Van Munster, Erik Th L ^c   Hupperts, Raymond M M ^d   Sanders, Evert A C M ^e   Mostert, Jop ^f   Sinnige, Okke L G F ^g   De Graaf, Jaap ^h   Pop, Paul ⁱ   Miltenburger, Carolin ^j   Groot, Martijn T ^k   Relleke, Milon ^k   Van Der Hel, W S ^k  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OptumInsight   (Sweden)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

^e Lievensberg Hospital   (Netherlands)

^f RIJNSTATE HOSPITAL   (Netherlands)

^g MEDICAL CENTER LEEUWARDEN   (Netherlands)

^h ISALA HOSPITAL   (Netherlands)

ⁱ VieCurie Medisch Centrum   (Netherlands)

^j OptumInsight   (Germany)

^k Novartis Pharma BV   (Netherlands)

more..

Author keywords

Activities of daily living; Costs; Fatigue; MS; Multiple sclerosis; Netherlands; Utility

Indexed keywords

NATALIZUMAB; NON PRESCRIPTION DRUG; STEROID;

ADULT; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; EXPERIENCE; FATIGUE; FEMALE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NETHERLANDS; QUALITY OF LIFE;

ACTIVITIES OF DAILY LIVING; ADULT; COMORBIDITY; COST OF ILLNESS; DISEASE PROGRESSION; EMPLOYMENT; FATIGUE; FEMALE; HEALTH SERVICES; HUMANS; INTERNET; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NETHERLANDS; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SICK LEAVE;

EID: 84879753084     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.807267     Document Type: Article

References (30)

1. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol Official J Eur Fed Neurol Soc 2006;13:700-22
2. Koutsouraki E, Costa V, Baloyannis S. Epidemiology of multiple sclerosis in Europe: a review. Int Rev Psychiatry 2010;22:2-13
3. Multiple Sclerosis International Federation. Atlas of MS Database. Total Number of people with MS in the Netherlands, 2008 data. http://www.atla-sofms. org. Accesed November 2012
4. Lalmohamed A, Bazelier MT, Van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 2012
5. Duddy M, Haghikia A, Cocco E, et al. Managing MS in a changing treatment landscape. J Neurol 2011;258:28-39
6. Kobelt G, Kasteng F. Access to Innovative treatments in multiple sclerosis in Europe. 2009. Comparator reports. http://www.comparatorreports. se/Access%20to%20MS%20treatments%20-%20October%202009.pdf. Accessed November 2012
7. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79
8. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008;14:1091-8
9. European Medicines Agency. 2011. http://www.ema.europa.eu. Accessed September 2011
10. U.S. Food and Drug Administration. 2011. http://www.fda.gov/NewsEvents/ NewsroomPressAnnouncements/ucm226755.htm. Accessed September 2011
11. Johansson E, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France. Mult Scler 2012;18:17-22
12. Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11-25
13. Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler 2012;18:35-9
14. Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany. Mult Scler 2012;18:23-7
15. Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler 2012;18:29-34
16. Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Mult Scler 2012;18:41-5
17. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1955;5:580-3
18. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 2006;7(Suppl 2):S5-13
19. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7(Suppl 2):S55-64
20. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenon-derzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2010. Instituut voor Medical Technology Assessment, Erasmus MC in opdracht van College voor zorgverzekeringen. ErasmusUniversiteit Rotterdam. The Netherlands. http://www.cvz.nl/binaries/live/cvzinternet/hst-content/nl/documenten/ losse-publicaties/handleiding-kostenonderzoek-2010.pdf. Accessed November 2012
21. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004. [Handbook for cost studies: methods and standard costs for economic evaluation in health care. Updated version 2004]. Instituut voor Medical Technology Assessment, Erasmus MC in opdracht van College voor zorgverzekeringen. ErasmusUniversiteit Rotterdam. The Netherlands. http://www.ispor.org/peguidelines/source/ Methodenenstandaardkostprijzenvooreconomischeeval-uatiesindegezondheidszorg.pdf. Accessed November 2012
22. Medicijnkosten. 2012. http://www.medicijnkosten.nl/. Accessed November 2012
23. OECD-Average annual hours worked. 2011. http://stats.oecd.org/Index.aspx? DataSetCode=ANHRS. Accessed November 2012
24. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77: 918-26
25. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
26. Dolan P, Gudex C, Kind P, et al. A social tariff for EuroQol: results from a UK General Population Survey. York: Centre for Health Economics, Universityof York, 1995
27. Meads DM, Doward LC, McKenna SP, et al. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler 2009;15: 1228-38
28. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 2007;13:1176-82
29. Minderhoud JM. On the pathogenesis of multiple sclerosis. A revised model of the cause(s) of multiple sclerosis, especially based on epidemiological data. Clin Neurol Neurosurg 1994;96:135-42
30. Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Multe Scler 2012;18:7-15